Cost-effectiveness analysis of pneumococcal vaccination for infants in China

• Published in: Vaccine Vol. 34; no. 50; pp. 6343 - 6349
• Main Authors: Maurer, Kristin A, Chen, Huey-Fen, Wagner, Abram L, Hegde, Sonia T, Patel, Tejasi, Boulton, Matthew L, Hutton, David W
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 07-12-2016; Elsevier Limited
• Subjects: 13-valent pneumococcal vaccine; Allergy and Immunology; Babies; China; China - epidemiology; Cost analysis; Cost-Benefit Analysis; Cost-effectiveness analysis; Ear diseases; Heptavalent Pneumococcal Conjugate Vaccine - administration & dosage; Heptavalent Pneumococcal Conjugate Vaccine - economics; Humans; Immunization; Infant; Infants; Markov chains; Meningitis; Mortality; Otitis media; Pneumococcal Infections - economics; Pneumococcal Infections - epidemiology; Pneumococcal Infections - prevention & control; Pneumococcal Vaccines - administration & dosage; Pneumococcal Vaccines - economics; Pneumonia; Sensitivity analysis; Streptococcus infections; Streptococcus pneumoniae; Studies; Vaccination - economics; Vaccines; South Africa; China; China, People's Rep; Cost-effectiveness analysis; Meningitis; Otitis media; Pneumonia; 13-valent pneumococcal vaccine; China
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2016.10.051

Highlights • China does not have a publicly funded pneumococcal vaccination program for infants. • We evaluated the cost-effectiveness of adding PCV-7, PCV-10 and PCV-13 to the EPI. • From the societal perspective, all vaccination programs are cost-effective. • A PCV-13 program is most cost-effective and should be implemented in China.